Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA synthetic ketamine schedule I placement of 2-fluorodeschloroketamine reflects urgent regulatory action on novel psychoactive substances. This temporary scheduling addresses abuse potential and lack of accepted medical use. Clinicians should stay…
Diphenidine Scheduling Update Under DEA Controlled Substances Act
The diphenidine DEA scheduling update marks a significant regulatory action under the Controlled Substances Act. This update highlights the evolving policy landscape for synthetic dissociative drugs. Understanding this scheduling update is critical for…
Study links commercial cannabis markets to increased addiction – News-Medical.Net
✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyMental HealthTHCIndustryDosing Why This Matters Clinicians need to understand that commercial…
Is Marijuana Addictive or Safe for Long-Term Use?
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. SafetyResearchMental HealthTHCNeurologyDosingPolicy Why This Matters Clinicians need accurate information about cannabis…
Is CBD Safe for Teens? Risks, Side Effects, and the Law
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CBDSafetyPediatricsResearchTHCMental HealthPolicy Why This Matters Clinicians need evidence-based guidance on CBD safety…
CED Cannabis Science Digest: 3 Lower-Certainty Signals Worth Watching
No fresh cannabis paper cleared CED Clinic's high-threshold lead-post bar on June 18, 2026, but three verified lower-certainty signals on insomnia, impaired driving, and legal-market pricing were still worth preserving. The cannabis insomnia trial…
Dr. Hance Clarke on The Medical Cannabis Real-World Evidence Study & Catherine Iniss …
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchPainAnxietySleepSafetyPolicyMental Health Clinical Summary # Clinical Summary The University Health Network is…
Medical Cannabis Pain Treatment as Part of a Modern Wellness Strategy
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainSafetyResearchCBDTHCDosingMental Health Why This Matters Clinicians need to understand that medical cannabis…
GLP-1 Receptor Agonist: Clinical Evidence and Outcomes
GLP-1 receptor agonist cancer risk reduction is an emerging area of clinical research. Recent studies suggest these medications may lower the incidence of certain cancers beyond their metabolic effects. Understanding this potential benefit can aid…
GLP-1 Receptor Agonist Clinical Evidence and FDA Enforcement
FDA enforcement action GLP-1 highlights critical safety concerns for compounded medications. Clinicians must prioritize FDA-approved receptor agonists for consistent dosing and quality. Understanding these actions supports safer prescribing and patient…